Literature DB >> 1638201

Non-Hodgkin's lymphoma. II: Management problems.

S E O'Reilly1, J M Connors.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1638201      PMCID： PMC1882475          DOI： 10.1136/bmj.305.6844.39

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

Review 1.  Non-Hodgkin's lymphoma. I: Characterisation and treatment.

Authors:  S E O'Reilly; J M Connors
Journal:  BMJ       Date:  1992-06-27

2.  The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.

Authors:  J M Vose; J O Armitage; D D Weisenburger; P J Bierman; S Sorensen; M Hutchins; D F Moravec; D Howe; M D Dowling; J Mailliard
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

3.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

4.  An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.

Authors:  I T Magrath; C Janus; B K Edwards; R Spiegel; E S Jaffe; C W Berard; J Miliauskas; K Morris; R Barnwell
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

5.  Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma.

Authors:  S E O'Reilly; P Klimo; J M Connors
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

6.  Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

Authors:  E C Kohn; R G Steis; E A Sausville; S R Veach; J L Stocker; R Phelps; S Franco; D L Longo; P A Bunn; D C Ihde
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

7.  Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings.

Authors:  D D Weisenburger; W G Sanger; J O Armitage; D T Purtilo
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.

Authors:  F Cabanillas; F B Hagemeister; G P Bodey; E J Freireich
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

9.  Treatment of lymphoblastic lymphoma in adults.

Authors:  C N Coleman; V J Picozzi; R S Cox; K McWhirter; L M Weiss; J R Cohen; K P Yu; S A Rosenberg
Journal:  J Clin Oncol       Date:  1986-11       Impact factor: 44.544

10.  Non-Hodgkin's lymphomas of head and neck extranodal sites.

Authors:  C Jacobs; R T Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-02       Impact factor: 7.038
View more
  2 in total

1.  Primary small bowel non-Hodgkin's lymphoma with biliary and pancreatic duct obstruction.

Authors:  M Suri; A Sharma; H P Sachdev; R K Puri
Journal:  Indian J Pediatr       Date:  1994 Jan-Feb       Impact factor: 1.967

2.  Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.

Authors:  J H Youngson; J M Jones; J G Chang; M Harris; S S Banergee
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.